Abstract
Epidermal Growth Factor Receptor (EGFR) tyrosine kinase inhibitors (TKIs) have changed the paradigm of treatment in non-small cell lung cancer (NSCLC). The molecular biology study of EGFR has led to clinical trials that select patients more accurately, regarding the presence of EGFR activating mutations. Nonetheless, a lack of response or a temporary condition of the response has been detected in patients on EGFR TKIs. This has urged to study potential resistance mechanisms underneath. The most important ones are the presence of secondary mutations in EGFR, such as T790M, or the overexpression of mesenchymal-epithelial transition factor (MET) that may explain why patients who initially respond to EGFR TKIs, may ultimately become refractory. Several approaches have been taken and new drugs both targeting EGFR resistance-mutation or MET are currently being developed. Here we review and update the EGFR biological pathway as well as the clinical data leading to approval of the EGFR TKIs currently in the market. New compounds under investigation targeting resistance mutations or dually targeting EGFR and other relevant receptors are also reviewed and discussed.
Keywords: Activity mutations, epidermal growth factor receptor, tyrosine kinase inhibitors.
Current Drug Targets
Title:Epidermal Growth Factor Receptor Targeting in Non-Small Cell Lung Cancer: Revisiting Different Strategies Against the Same Target
Volume: 15 Issue: 14
Author(s): Eduardo Castanon, Patricia Martin, Christian Rolfo, Juan P. Fusco, Lucia Ceniceros, Jairo Legaspi, Marta Santisteban and Ignacio Gil-Bazo
Affiliation:
Keywords: Activity mutations, epidermal growth factor receptor, tyrosine kinase inhibitors.
Abstract: Epidermal Growth Factor Receptor (EGFR) tyrosine kinase inhibitors (TKIs) have changed the paradigm of treatment in non-small cell lung cancer (NSCLC). The molecular biology study of EGFR has led to clinical trials that select patients more accurately, regarding the presence of EGFR activating mutations. Nonetheless, a lack of response or a temporary condition of the response has been detected in patients on EGFR TKIs. This has urged to study potential resistance mechanisms underneath. The most important ones are the presence of secondary mutations in EGFR, such as T790M, or the overexpression of mesenchymal-epithelial transition factor (MET) that may explain why patients who initially respond to EGFR TKIs, may ultimately become refractory. Several approaches have been taken and new drugs both targeting EGFR resistance-mutation or MET are currently being developed. Here we review and update the EGFR biological pathway as well as the clinical data leading to approval of the EGFR TKIs currently in the market. New compounds under investigation targeting resistance mutations or dually targeting EGFR and other relevant receptors are also reviewed and discussed.
Export Options
About this article
Cite this article as:
Castanon Eduardo, Martin Patricia, Rolfo Christian, Fusco P. Juan, Ceniceros Lucia, Legaspi Jairo, Santisteban Marta and Gil-Bazo Ignacio, Epidermal Growth Factor Receptor Targeting in Non-Small Cell Lung Cancer: Revisiting Different Strategies Against the Same Target, Current Drug Targets 2014; 15 (14) . https://dx.doi.org/10.2174/138945011514141216092935
DOI https://dx.doi.org/10.2174/138945011514141216092935 |
Print ISSN 1389-4501 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-5592 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Salinomycin Modulates the Expression of mRNAs and miRNAs Related to Stemness in Endometrial Cancer
Current Pharmaceutical Biotechnology Exploiting EPR in Polymer Drug Conjugate Delivery for Tumor Targeting
Current Pharmaceutical Design MicroRNA-34 Family, Mechanisms of Action in Cancer: A Review
Current Cancer Drug Targets Role of Cytokines in Regulating Feeding Behaviour
Current Drug Targets Gene Therapy for Gastric Diseases
Current Gene Therapy Advances in Immuno-PET for the Detection of Cancer and Assessment of Response to Therapy
Current Medicinal Chemistry Optimizing Outcomes Following Allogeneic Hematopoietic Progenitor Cell Transplantation in AML: The Role of Hypomethylating Agents
Current Cancer Drug Targets Cordycepin in Anticancer Research: Molecular Mechanism of Therapeutic Effects
Current Medicinal Chemistry Analysis of the Relative Movements Between EGFR and Drug Inhibitors Based on Molecular Dynamics Simulation
Current Bioinformatics Pluronic-Based Core/Shell Nanoparticles for Drug Delivery and Diagnosis
Current Medicinal Chemistry Alkaloids as Important Scaffolds in Therapeutic Drugs for the Treatments of Cancer, Tuberculosis, and Smoking Cessation
Current Topics in Medicinal Chemistry MicroRNAs in Cancer Gene Therapy: Another Look
Current Cancer Therapy Reviews Editorial [Hot Topic: Oncohematology: From Bench to Bedside (Guest Editor: Vincenzo De Feo)]
Mini-Reviews in Medicinal Chemistry Protein Kinases as Tumor Biomarkers and Therapeutic Targets
Current Pharmaceutical Design Ghrelin and the Brain-gut Axis as a Pharmacological Target for Appetite Control
Current Pharmaceutical Design Recent Advances in Small Molecule Inhibitors of VEGFR and EGFR Signaling Pathways
Current Topics in Medicinal Chemistry iHyd-PseAAC (EPSV): Identifying Hydroxylation Sites in Proteins by Extracting Enhanced Position and Sequence Variant Feature via Chou's 5- Step Rule and General Pseudo Amino Acid Composition
Current Genomics Cranberry as Promising Natural Source of Potential Anticancer Agents: Current Evidence and Future Perspectives
Anti-Cancer Agents in Medicinal Chemistry The De Novo Synthesis of Oligosaccharides: Application to the Medicinal Chemistry SAR-Study of Digitoxin
Current Topics in Medicinal Chemistry NKT Cell Subsets Can Exert Opposing Effects in Autoimmunity, Tumor Surveillance and Inflammation
Current Immunology Reviews (Discontinued)